Citadel Advisors
LSTA icon

Citadel Advisors’s Lisata Therapeutics LSTA Stock Holding History

Citadel Advisors’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,093
Closed -$12K – 13596
2022
Q1 		$12K Sell
1,093
-534
-33% -$6.11K ﹤0.01% 13357
2021
Q4 		$21K Sell
1,627
-3,266
-67% -$50.4K ﹤0.01% 13577
2021
Q3 		$90K Sell
4,893
-727
-13% -$14.3K ﹤0.01% 12978
2021
Q2 		$136K Buy
5,620
+473
+9% +$11.2K ﹤0.01% 12605
2021
Q1 		$149K Buy
5,147
+2,720
+112% +$82.4K ﹤0.01% 12041
2020
Q4 		$52K Sell
2,427
-1,940
-44% -$46K ﹤0.01% 10552
2020
Q3 		$118K Buy
4,367
+2,760
+172% +$87.3K ﹤0.01% 9171
2020
Q2 		$43K Buy
+1,607
New +$47.3K ﹤0.01% 9365
2015
Q3 		– Sell
-31
Closed -$9K – 9081
2015
Q2 		$9K Buy
31
+2
+7% +$743 ﹤0.01% 8438
2015
Q1 		$11K Sell
29
-5
-15% -$2.71K ﹤0.01% 8171
2014
Q4 		$19K Sell
34
-6
-15% -$4.08K ﹤0.01% 7847
2014
Q3 		$33K Sell
40
-11
-22% -$9.63K ﹤0.01% 7156
2014
Q2 		$50K Buy
51
+33
+183% +$32.1K ﹤0.01% 6740
2014
Q1 		$19K Buy
+18
New +$19.5K ﹤0.01% 7311

Other funds holding LSTA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GS
GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return

Citadel Advisors's LSTA Position: Q2 2026 in Review

Citadel Advisors reduced its Lisata Therapeutics (LSTA) stake by 31% in Q2 2026, selling an estimated $25.4K and leaving 15,541 shares worth $52.8K. The position accounts for ﹤0.01% of the portfolio, ranked #13088.

Citadel Advisors first reported a position in LSTA in Q1 2014 and has held it in 19 quarters since. The position peaked at $128K in Q4 2014. 31 funds tracked by Wall St. Rank hold LSTA as of Q2 2026.

  • Citadel Advisors held 15,541 shares of Lisata Therapeutics worth $52.8K as of Q2 2026.
  • Citadel Advisors sold 7,125 Lisata Therapeutics shares in Q2 2026, an estimated $25.4K.
  • Lisata Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13088 holding.
  • Citadel Advisors first reported a position in Lisata Therapeutics in Q1 2014 and has held it in 19 quarters since.
  • Citadel Advisors's Lisata Therapeutics position peaked at $128K in Q4 2014.
  • 31 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.